New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
09:14 EDTPATH, FRX, TWTR, STZ, MCD, JCP, MSFT, TCS, TEVA, RAD, F, ENDP, MUOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Micron (MU), up 10%... Constellation Brands (STZ), up 7%... Apollo Education (APOL), up 8%. ALSO HIGHER: Forest Laboratories (FRX), up 14% after acquiring Aptalis for $2.9B in cash... Rite Aid (RAD), up 2.6% following upgrade at JPMorgan... NuPathe (PATH), up 36% after receiving takeover bid from Teva (TEVA) to rival formerly agreed to deal with Endo Health (ENDP)... Ford (F), up 1.6% after AP says CEO Mulally staying at Ford. Microsoft (MSFT), down 0.6% after the news, as Mulally was viewed as a candidate for its CEO opening... ALSO LOWER: The Container Store (TCS), down 10.4% after earnings, downgrade at BofA Merrill Lynch... J.C. Penney (JCP), down 6.3% after backing Q4 outlook but not providing December same-store sales figure... Twitter (TWTR), down 4% following downgrade at Cantor... McDonald's (MCD), down 1% following downgrade at Wells Fargo.
News For TWTR;F;MSFT;FRX;RAD;JCP;PATH;TEVA;MCD;MU;TCS;STZ;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
June 16, 2015
14:23 EDTTEVAReceptos price target raised to $348 at Wedbush on M&A potential
Wedbush analysts Liana Moussatos and Kelechi Chikere said they'd interpreted Receptos (RCPT) comments with its earnings report in May about its ability to commercialize ozanimod on its own as a message to potential buyers that their bids were too low. Following a recent report from Proactive Investors, which claimed that Receptos had turned down bids of $200 per share from AstraZeneca (AZN) and $280 per share from Teva (TEVA) and Gilead (GILD), the analysts said they have reconsidered their valuation assumptions, as they believe these bid values could be accurate. Wedbush raised its fair value estimate on Receptos to $348 from $211, citing a belief in increased industry interest in ozanimod and the rest of Receptos’ pipeline, and maintains an Outperform rating on the stock.
14:12 EDTTEVAAbbott backing marginally ups chances of Mylan-Perrigo deal, says BMO Capital
Subscribe for More Information
13:56 EDTTWTRTwitter hits 52-week low after MKM downgrades on user growth concerns
Subscribe for More Information
13:24 EDTTWTRTwitter's Costolo says CEO search should be 'out in the open,' Bloomberg reports
Subscribe for More Information
12:04 EDTMSFTBox enhances integration with Microsoft Office Online
Box (BOX) announced a deep integration with Microsoft (MSFT) Office Online that will transform collaboration for joint customers. The company added, "Today’s update extends the reach of Box’s powerful integrations with Office 365 for the desktop, Office on iOS and Outlook, and demonstrates Box’s commitment to the Office 365 Cloud Storage Partner Program." “Box and Microsoft are working together to help businesses and individuals be more productive, collaborative and successful,” said Kirk Koenigsbauer, corporate vice president for Office at Microsoft. “We're thrilled about this latest offering to give our joint customers more choice and simplicity for how they work together with documents and digital content.” The Box integration with Office Online will enable users to easily browse, open and edit Office Online files directly from Box, as well as automatically save all changes made in Office Online back to Box in real-time. Together, these enhancements eliminate the need to upload or download files or move back-and-forth between applications, simplifying workflows and mitigating the security risks that come with locally stored content.
11:06 EDTTEVATeva says 'fully committed' to bid for Mylan, Bloomberg reports
After Abbott (ABT) announced earlier that it intends to vote its 14.5% stake in Mylan (MYL) in favor of Mylan's proposed acquisition of Perrigo (PRGO), a Teva (TEVA) spokesperson told Bloomberg in an email that the company remains "fully committed" to is offer to acquire Mylan, which Teva said is better than Mylan's suggested deal for Perrigo.
11:06 EDTTWTRTwitter introduces autoplay video and new viewability standard
Subscribe for More Information
11:02 EDTTWTRStocks with call strike movement; TWTR FEYE
RT Options Scanner shows Twitter (TWTR) September 39 call option implied volatility increased 4% to 46, FireEye (FEYE) December 60 call option implied volatility increased 3% to 46 according to IVolatility.
10:29 EDTTEVAGeneric drugs may be targets of congressional price probe, Bloomberg says
In addition to branded drugs that were cited for "staggering" price increases in a congressional probe on drug prices being led by U.S. Senator Bernie Saunders, generic drug makers may also be targeted, stated Bloomberg Intelligence. Data show some generics, including clomipramine hydrochloride and tetracycline, have seen "aggressive" quarterly price increases, the report noted. Generic drug makers that could be caught up in the probe include Mallinckrodt (MNK), Teva (TEVA), Novartis' (NVS) Sandoz unit, Mylan (MYL), Taro Pharmaceutical (TARO) and Teva (TEVA). Mallinckrodt shares are down about 4% in early trading.
10:01 EDTTWTRTwitter hits a new 52-week low, levels to watch
Subscribe for More Information
10:01 EDTTWTROn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AIG (AIG) downgraded to Hold from Buy at Deutsche Bank... Alumina (AWCMY) downgraded to Neutral from Outperform at Credit Suisse... Avalanche Biotechnologies (AAVL) downgraded on lack of catalysts at SunTrust... DealerTrack (TRAK) downgraded to Hold from Buy at Craig-Hallum... Greenbrier (GBX) downgraded to Hold from Buy at Stifel... Methode Electronics (MEI) downgraded to Neutral at Baird... Profire Energy (PFIE) downgraded to Hold from Buy at Maxim... Standard Pacific (SPF) downgraded to Neutral from Outperform at Credit Suisse... The Fresh Market (TFM) downgraded to Sell from Neutral at Northcoast... Twitter (TWTR) downgraded to Neutral at MKM Partners on stalled user growth... United Natural Foods (UNFI) downgraded to Hold from Buy at Argus... United Rentals (URI) downgraded to Underperform from Neutral at Macquarie.
09:46 EDTMSFTMicrosoft to encrypt all search traffic by default
Microsoft's Bing has announced that it will encrypt its search traffic by default. Bing has already been offering users the option to encrypt search traffic for about a year and a half now. Beginning this summer, Bing will begin the process of encrypting search traffic by default. With the move to encrypted search by default Bing will continue to pass along a referrer string so that marketers and webmasters will be able to identify traffic as coming from Bing. However, to further protect users’ privacy, Bing will not include the used query terms. Reference Link
09:36 EDTTWTRActive equity options trading on open
Subscribe for More Information
09:17 EDTMUMicron estimates lowered again at Cleveland Research
Cleveland Research lowered Neutral rated Micron estimates again due to continued PC and server DRAM pricing pressure. The firm said PC and server DRAM inventory remains oversupplied and Mobile demand is softer and in oversupply. Cleveland Research recommends remaining on the on the sidelines for Micron and expects additional meaningful estimate reductions.
08:05 EDTTEVATeva reports ARM-TD study meets primary endpoint
Teva Pharmaceutical (TEVA) announced positive top-line results from the pivotal clinical study Aim to Reduce Movements in Tardive Dyskinesia, or ARM-TD, designed to evaluate the efficacy of SD-809 in the treatment of moderate to severe tardive dyskinesia. Top-line data showed that the study met its primary endpoint and demonstrated a positive trend in all secondary endpoints. The primary endpoint of ARM-TD was the change in the Abnormal Involuntary Movement Scale, or AIMS, from baseline to end of therapy, assessed by blinded centralized video rating. The study results show patients taking SD-809 achieved an improvement of 3.0 points on the AIMS score from baseline to end of therapy compared to 1.6 points in placebo for a clinically meaningful effect. Study results also demonstrated a favorable safety and tolerability profile of SD-809. Fewer patients taking SD-809 than placebo experienced serious adverse events. Three patients discontinued from the study for adverse events. For all other side effects reported in the study, rates in the SD-809 group were similar or lower than the placebo group. Further analysis of the additional data from the study is ongoing and details will be shared at future medical meetings and through peer-reviewed publication, the company said. SD-809 became part of Teva’s central nervous system product portfolio with the acquisition of Auspex Pharmaceuticals in May.
07:51 EDTTWTRTwitter downgraded to Neutral at MKM Partners on stalled user growth
As previously reported, MKM Partners analyst Rob Sanderson downgraded Twitter (TWTR) to Neutral from Buy, noting that growth in its user base is stalling out and he sees no catalyst for sentiment to improve in the next two quarters, besides a possible bid from Google (GOOG). Sanderson thinks the company's CEO search brings with it some uncertainty and likely delays user experience improvements, unless Jack Dorsey takes over full-time, but that would require him to give up his CEO post at Square. The firm lowered its estimates on Twitter and cut its price target on the shares to $39 from $57.
07:31 EDTTEVAEagle Pharmaceuticals price target raised to $95 from $65 at Cantor
Subscribe for More Information
06:27 EDTMSFTMicrosoft opens branded store on Indian e-commerce platform Snapdeal
Subscribe for More Information
06:24 EDTTWTRTwitter downgraded to Neutral from Buy at MKM Partners
Subscribe for More Information
05:53 EDTTWTRStocks with implied volatility above IV index mean; TWTR AA
Stocks with implied volatility above IV index mean; Twitter (TWTR) 32, Alcoa (AA) 32 according to iVolatility.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use